Name | Ontuxizumab |
---|
Description | Ontuxizumab (MORAb-004) is a humanized IgG1/κ anti-endosialin (TEM-1 or CD248) monoclonal antibody with antitumor effects. Ontuxizumab can be used for the research of cancer[1]. |
---|---|
Related Catalog | |
In Vitro | Ontuxizumab (0-100 μg/mL;12 小时) 诱导 CD248 内化并剂量依赖性地降低了 46% 的人周皮细胞表面的 CD248[1]。 |
In Vivo | Ontuxizumab (50 mg/kg;静脉注射,每天 5 次,连续 5 天) 在人 CD248 敲入小鼠显示抗肿瘤作用[1]。 Animal Model: Human CD248 knock-in mice[1] Dosage: 50 mg/kg Administration: Intravenous injection via tail vein; 50 mg/kg, 5 doses daily for 5 consecutive days Result: Reduced tumor growth with a lower level of CD248 and α-SMA on neovasculature pericytes. |
References |
No Any Chemical & Physical Properties |